NASDAQ:ENDP - Endo International Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $7.67
Forecasted Upside: 36.66 %
Number of Analysts: 7
Breakdown:
2 Sell Ratings
3 Hold Ratings
2 Buy Ratings
0 Strong Buy Ratings

^$5.61 As of 05/14/2021 01:00 AM ET

▲ +0.08 (1.45%)

1 month | 3 months | 12 months

Get New Endo International Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ENDP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENDP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$7.67

▲ +36.66% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for Endo International in the last 3 months. The average price target is $7.67, with a high forecast of $12.00 and a low forecast of $3.00. The average price target represents a 36.66% upside from the last price of $5.61.

Hold

The current consensus among 7 contributing investment analysts is to hold stock in Endo International. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
4 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

11/23/2019

0 strong buy ratings
4 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

2/21/2020

0 strong buy ratings
3 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

5/21/2020

0 strong buy ratings
4 buy ratings
1 hold ratings
2 sell ratings

Ratings as of

8/19/2020

0 strong buy ratings
4 buy ratings
1 hold ratings
2 sell ratings

Ratings as of

11/17/2020

0 strong buy ratings
3 buy ratings
2 hold ratings
2 sell ratings

Ratings as of

2/15/2021

0 strong buy ratings
3 buy ratings
3 hold ratings
2 sell ratings

Ratings as of

4/16/2021

0 strong buy ratings
2 buy ratings
3 hold ratings
2 sell ratings

Ratings as of

5/16/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
4/7/2021	Royal Bank of Canada	Initiated Coverage	Sector Perform	$7.00	High	i
3/9/2021	Morgan Stanley	Boost Price Target	Underweight	$5.00 ➝ $7.00	High	i
3/8/2021	Barclays	Boost Price Target	Positive ➝ Equal Weight	$6.00 ➝ $7.00	High	i
3/4/2021	Citigroup	Lower Price Target		$11.00 ➝ $10.00	High	i
3/3/2021	Morgan Stanley	Boost Price Target	Underweight	$5.00 ➝ $7.00	High	i
2/8/2021	SVB Leerink	Reiterated Rating	Market Perform		Low	i Rating by A. Fadia at SVB Leerink LLC
1/19/2021	Citigroup	Boost Price Target		$7.00 ➝ $9.00	High	i
1/4/2021	Piper Sandler	Boost Price Target	Overweight	$6.00 ➝ $12.00	N/A	i
11/12/2020	Morgan Stanley	Boost Price Target	Underweight	$3.00 ➝ $4.00	Medium	i
10/9/2020	Piper Sandler	Boost Price Target	Overweight	$5.00 ➝ $6.00	High	i
7/27/2020	The Goldman Sachs Group	Initiated Coverage	Sell	$3.00	High	i
7/8/2020	SunTrust Banks	Reiterated Rating	Buy		High	i
6/11/2020	Royal Bank of Canada	Reiterated Rating	Hold	$6.00	Medium	i
5/10/2020	Royal Bank of Canada	Reiterated Rating	Hold	$6.00	Low	i
4/24/2020	Citigroup	Initiated Coverage	Buy	$7.00	High	i
4/15/2020	Piper Sandler	Lower Price Target	Overweight	$7.00 ➝ $6.00	Medium	i
4/2/2020	Royal Bank of Canada	Reiterated Rating	Hold	$6.00	Low	i
4/2/2020	Morgan Stanley	Lower Price Target	Underweight	$4.00 ➝ $3.00	Low	i
1/3/2020	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight	$5.00 ➝ $7.00	Low	i
8/9/2019	Morgan Stanley	Set Price Target	Sell	$2.00	N/A	i Rating by David Risinger at Morgan Stanley
8/8/2019	Royal Bank of Canada	Reiterated Rating	Hold	$6.00	High	i Rating by Randall Stanicky at Royal Bank of Canada
8/7/2019	Mizuho	Reiterated Rating	Hold	$6.00	High	i Rating by Irina Rivkind Koffler at Mizuho
7/31/2019	Mizuho	Reiterated Rating	Hold	$6.00	High	i Rating by Irina Rivkind Koffler at Mizuho
7/15/2019	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$8.00 ➝ $3.00	Medium	i
7/11/2019	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$11.00 ➝ $6.00	High	i
6/17/2019	Citigroup	Downgrade	Buy ➝ Neutral	$19.00 ➝ $5.00	Medium	i
6/12/2019	Cantor Fitzgerald	Lower Price Target	Neutral	$18.00 ➝ $4.75	High	i
6/11/2019	Barclays	Initiated Coverage	Equal Weight ➝ Equal Weight	$6.00	High	i
5/15/2019	Canaccord Genuity	Lower Price Target	Buy	$17.00 ➝ $15.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
5/14/2019	Mizuho	Set Price Target	Hold	$9.00	Low	i Rating by Irina Rivkind Koffler at Mizuho
5/13/2019	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$9.00	High	i
3/27/2019	Gabelli	Reiterated Rating	Hold		Medium	i Rating by K. Kedra at Gabelli
3/19/2019	SunTrust Banks	Initiated Coverage	Buy ➝ Buy	$13.00	Medium	i
3/18/2019	JPMorgan Chase & Co.	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $10.00	Low	i
3/8/2019	Canaccord Genuity	Set Price Target	Buy	$17.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
3/5/2019	SVB Leerink	Downgrade	Outperform ➝ Market Perform		Low	i Rating by A. Fadia at SVB Leerink LLC
3/1/2019	Piper Jaffray Companies	Reiterated Rating	Hold		High	i Rating by David Amsellem at Piper Jaffray Companies
11/26/2018	Mizuho	Lower Price Target	Neutral	$15.00	High	i
11/9/2018	Canaccord Genuity	Upgrade	Hold ➝ Buy	$16.00 ➝ $20.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
11/9/2018	Cowen	Reiterated Rating	Hold	$9.00	Low	i
10/19/2018	Cantor Fitzgerald	Boost Price Target	Neutral ➝ Neutral	$12.00 ➝ $18.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
9/11/2018	The Goldman Sachs Group	Upgrade	Sell ➝ Neutral	$14.00 ➝ $15.00	Low	i Rating by Dana Flanders at The Goldman Sachs Group, Inc.
8/17/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $17.00	Low	i
8/14/2018	Mizuho	Boost Price Target	Neutral	$17.00	Low	i
8/13/2018	Canaccord Genuity	Reiterated Rating	Hold ➝ Hold	$13.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
8/13/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$26.00	High	i
8/10/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$9.00 ➝ $16.00	Low	i
8/9/2018	SVB Leerink	Boost Price Target	Outperform ➝ Market Perform	$12.00 ➝ $18.00	High	i
8/9/2018	Stifel Nicolaus	Boost Price Target	Hold ➝ Hold	$10.00 ➝ $17.00	Low	i
8/9/2018	Citigroup	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $19.00	Low	i Rating by Liav Abraham at Citigroup Inc.
8/8/2018	Cantor Fitzgerald	Set Price Target	Hold	$12.00	High	i Rating by Louise Chen at Cantor Fitzgerald
8/7/2018	B. Riley	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00	Low	i Rating by D. Buck at B. Riley
8/1/2018	Canaccord Genuity	Set Price Target	Hold	$13.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
7/23/2018	Cantor Fitzgerald	Set Price Target	Hold	$12.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
7/18/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$11.00	Low	i Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
7/11/2018	Citigroup	Reiterated Rating	Buy		Low	i Rating by Liav Abraham at Citigroup Inc.
6/28/2018	B. Riley	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $13.00	High	i Rating by D. Buck at B. Riley
6/27/2018	Citigroup	Upgrade	Neutral ➝ Buy	$11.00	High	i
6/1/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$10.00	Medium	i Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
5/13/2018	Oppenheimer	Reiterated Rating	Hold		Low	i Rating by Christopher Liu at Oppenheimer Holdings Inc.
5/8/2018	Canaccord Genuity	Set Price Target	Hold	$7.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
5/8/2018	Cantor Fitzgerald	Set Price Target	Hold	$7.00	High	i Rating by Louise Chen at Cantor Fitzgerald
4/4/2018	Mizuho	Downgrade	Buy ➝ Neutral	$12.00 ➝ $7.00	High	i
3/10/2018	Barclays	Set Price Target	Hold	$9.00	Low	i Rating by Douglas Tsao at Barclays PLC
3/5/2018	BMO Capital Markets	Lower Price Target	Market Perform ➝ Market Perform	$10.00 ➝ $9.00	High	i
2/28/2018	Gabelli	Downgrade	Buy ➝ Hold		High	i Rating by K. Kedra at Gabelli
2/27/2018	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Derek Archila at Oppenheimer Holdings Inc.
2/27/2018	Canaccord Genuity	Set Price Target	Hold	$7.00	High	i Rating by Dewey Steadman at Canaccord Genuity
2/27/2018	Cantor Fitzgerald	Set Price Target	Hold	$7.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
2/26/2018	JMP Securities	Downgrade	Outperform ➝ Market Perform		Low	i
2/23/2018	Barclays	Lower Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $10.00	High	i
2/21/2018	Canaccord Genuity	Set Price Target	Hold ➝ Hold	$8.00 ➝ $7.00	Medium	i Rating by Dewey Steadman at Canaccord Genuity
2/14/2018	B. Riley	Initiated Coverage	Buy ➝ Buy	$10.00	High	i Rating by D. Buck at B. Riley
1/11/2018	Cantor Fitzgerald	Set Price Target	Hold	$7.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
1/3/2018	Mizuho	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $12.00	High	i
1/2/2018	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$12.00	High	i Rating by A. Fadia at SVB Leerink LLC
12/12/2017	Guggenheim	Initiated Coverage	Neutral ➝ Neutral	$8.50	Low	i Rating by Louise Chen at Guggenheim
11/10/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$7.00	N/A	i
11/10/2017	Mizuho	Reiterated Rating	Buy		N/A	i
11/10/2017	BMO Capital Markets	Lower Price Target	Market Perform	$11.00 ➝ $10.00	N/A	i
11/10/2017	Cantor Fitzgerald	Lower Price Target	Neutral	$9.00 ➝ $7.00	N/A	i Rating by Louise Chen at Cantor Fitzgerald
11/10/2017	Citigroup	Lower Price Target	Neutral	$9.00 ➝ $7.00	N/A	i
11/10/2017	Royal Bank of Canada	Lower Price Target	Sector Perform ➝ Sector Perform	$9.00 ➝ $8.00	N/A	i Rating by Randall Stanicky at Royal Bank of Canada
10/30/2017	Cantor Fitzgerald	Set Price Target	Hold	$9.00	N/A	i Rating by Louise Chen at Cantor Fitzgerald
10/17/2017	Royal Bank of Canada	Set Price Target	Hold	$9.00	N/A	i Rating by Randall Stanicky at Royal Bank of Canada
9/28/2017	The Goldman Sachs Group	Initiated Coverage	Sell ➝ Sell	$7.00	High	i
9/17/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$9.00	Medium	i
9/12/2017	Mizuho	Reiterated Rating	Buy	$19.00 ➝ $14.00	Low	i
8/14/2017	Canaccord Genuity	Set Price Target	Hold	$10.00	High	i Rating by Dewey Steadman at Canaccord Genuity
8/11/2017	BMO Capital Markets	Reiterated Rating	Market Perform	$15.00 ➝ $11.00	Low	i
8/10/2017	Morgan Stanley	Lower Price Target	Equal Weight	$12.00 ➝ $8.00	Low	i
8/10/2017	Cowen	Reiterated Rating	Hold	$16.00	High	i
8/10/2017	Citigroup	Reiterated Rating	Neutral	$14.00 ➝ $11.00	High	i
8/10/2017	Mizuho	Reiterated Rating	Buy	$19.00	High	i
8/10/2017	Royal Bank of Canada	Set Price Target	Hold	$15.00 ➝ $9.00	High	i Rating by Randall Stanicky at Royal Bank of Canada
8/9/2017	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$15.00 ➝ $13.00	Low	i Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
8/9/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform	$15.00 ➝ $9.00	High	i Rating by Randall Stanicky at Royal Bank of Canada
8/8/2017	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Derek Archila at Oppenheimer Holdings Inc.
8/8/2017	Cantor Fitzgerald	Set Price Target	Hold	$12.00 ➝ $9.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
7/23/2017	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Derek Archila at Oppenheimer Holdings Inc.
7/16/2017	Royal Bank of Canada	Set Price Target	Hold	$15.00	Medium	i Rating by Randall Stanicky at Royal Bank of Canada
7/7/2017	Deutsche Bank Aktiengesellschaft	Lower Price Target	Buy	$18.00 ➝ $15.00	Medium	i
6/17/2017	Guggenheim	Initiated Coverage	Hold	$12.00	Medium	i Rating by Louise Chen at Guggenheim
6/16/2017	Cantor Fitzgerald	Initiated Coverage	Neutral ➝ Neutral	$12.00	Low	i
6/14/2017	William Blair	Reiterated Rating	Market Perform		Low	i
6/12/2017	Royal Bank of Canada	Set Price Target	Hold	$15.00	Low	i Rating by Randall Stanicky at Royal Bank of Canada
6/9/2017	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$22.00 ➝ $15.00	High	i
6/8/2017	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Derek Archila at Oppenheimer Holdings Inc.
6/8/2017	Canaccord Genuity	Set Price Target	Hold	$14.00 ➝ $12.00	High	i Rating by Dewey Steadman at Canaccord Genuity
5/25/2017	Mizuho	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $19.00	Low	i
5/22/2017	Canaccord Genuity	Set Price Target	Hold	$14.00	High	i Rating by Dewey Steadman at Canaccord Genuity
5/17/2017	BMO Capital Markets	Reiterated Rating	Hold	$16.00	High	i
5/11/2017	Canaccord Genuity	Set Price Target	Hold	$14.00	Medium	i Rating by Dewey Steadman at Canaccord Genuity
5/1/2017	Canaccord Genuity	Set Price Target	Hold	$14.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
5/1/2017	BMO Capital Markets	Reiterated Rating	Hold	$15.00	Low	i
4/17/2017	Canaccord Genuity	Reiterated Rating	Hold	$14.00	Low	i Rating by Dewey Steadman at Canaccord Genuity
4/13/2017	Mizuho	Reiterated Rating	Buy	$17.00 ➝ $18.00	Low	i
4/11/2017	Canaccord Genuity	Reiterated Rating	Hold	$14.00	High	i Rating by Dewey Steadman at Canaccord Genuity
4/8/2017	Royal Bank of Canada	Set Price Target	Hold	$15.00	Medium	i Rating by Randall Stanicky at Royal Bank of Canada
3/20/2017	SVB Leerink	Reiterated Rating	Market Perform		Low	i
3/15/2017	JMP Securities	Reiterated Rating	Outperform	$20.00	High	i Rating by Donald Ellis at JMP Securities
3/15/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform	$15.00	High	i
3/14/2017	Canaccord Genuity	Set Price Target	Hold	$14.00	High	i Rating by Dewey Steadman at Canaccord Genuity
3/11/2017	William Blair	Reiterated Rating	Market Perform		N/A	i
3/3/2017	Mizuho	Boost Price Target		$17.00	N/A	i
3/1/2017	Oppenheimer	Reiterated Rating	Hold		N/A	i Rating by Derek Archila at Oppenheimer Holdings Inc.
3/1/2017	Canaccord Genuity	Set Price Target	Hold	$14.00	N/A	i
2/28/2017	Mizuho	Reiterated Rating	Buy	$15.00 ➝ $17.00	N/A	i
2/28/2017	Guggenheim	Reiterated Rating	Buy	$35.00	N/A	i Rating by Louise Chen at Guggenheim
2/21/2017	Canaccord Genuity	Initiated Coverage	Hold ➝ Hold	$14.00	N/A	i
2/6/2017	Barclays	Lower Price Target	Equal Weight	$22.00 ➝ $15.00	N/A	i
1/31/2017	Susquehanna Bancshares	Upgrade	Neutral ➝ Positive		N/A	i
1/31/2017	Mizuho	Lower Price Target	Buy	$25.00 ➝ $15.00	N/A	i
1/30/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform	$18.00 ➝ $15.00	N/A	i
1/27/2017	Piper Jaffray Companies	Set Price Target	Hold	$12.00	N/A	i Rating by David Amsellem at Piper Jaffray Companies
1/20/2017	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$20.00	N/A	i Rating by chris schott at JPMorgan Chase & Co.
1/5/2017	Citigroup	Downgrade	Buy ➝ Neutral	$25.00 ➝ $20.00	N/A	i
12/11/2016	JMP Securities	Reiterated Rating	Outperform	$34.00	N/A	i
12/7/2016	Oppenheimer	Reiterated Rating	Market Perform		N/A	i Rating by Marcus Y. Ho at Oppenheimer Holdings Inc.
11/18/2016	JMP Securities	Reiterated Rating	Buy		N/A	i
11/11/2016	BMO Capital Markets	Reiterated Rating	Hold		N/A	i
11/11/2016	Mizuho	Lower Price Target	Buy	$29.00 ➝ $25.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
11/11/2016	JMP Securities	Reiterated Rating	Outperform	$44.00 ➝ $34.00	N/A	i
11/10/2016	Susquehanna Bancshares	Upgrade	Neutral ➝ Positive	$20.00	N/A	i
11/9/2016	Royal Bank of Canada	Reiterated Rating	Outperform	$26.00 ➝ $21.00	N/A	i
11/9/2016	Royal Bank of Canada	Lower Price Target	Outperform	$26.00 ➝ $21.00	N/A	i
11/8/2016	Oppenheimer	Reiterated Rating	Hold		N/A	i Rating by Marcus Y. Ho at Oppenheimer Holdings Inc.
10/15/2016	Guggenheim	Reiterated Rating	Buy	$35.00	N/A	i
9/29/2016	Northland Securities	Upgrade	Market Perform ➝ Outperform	$27.00	N/A	i
9/29/2016	Mizuho	Reiterated Rating	Outperform ➝ Sell	$29.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
9/27/2016	Oppenheimer	Reiterated Rating	Market Perform		N/A	i Rating by Rohit Vanjani at Oppenheimer Holdings Inc.
9/27/2016	Piper Jaffray Companies	Reiterated Rating	Neutral	$19.00	N/A	i Rating by david amsellem at Piper Jaffray Companies
9/23/2016	SVB Leerink	Reiterated Rating	Market Perform	$22.00	N/A	i Rating by jason gerberry at SVB Leerink LLC
9/19/2016	Mizuho	Reiterated Rating	Buy	$29.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
9/16/2016	Citigroup	Lower Price Target	Buy	$40.00 ➝ $25.00	N/A	i
9/8/2016	Morgan Stanley	Set Price Target	Hold	$15.00 ➝ $16.00	N/A	i Rating by david risinger at Morgan Stanley
8/12/2016	Mizuho	Upgrade	Neutral ➝ Buy	$16.00 ➝ $29.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
8/9/2016	JPMorgan Chase & Co.	Set Price Target	Buy	$40.00	N/A	i Rating by chris schott at JPMorgan Chase & Co.
8/9/2016	Piper Jaffray Companies	Set Price Target	Hold	$18.00 ➝ $19.00	N/A	i Rating by david amsellem at Piper Jaffray Companies
8/9/2016	SVB Leerink	Reiterated Rating	Hold	$23.00 ➝ $22.00	N/A	i Rating by Jason Gerberry at SVB Leerink LLC
8/9/2016	BMO Capital Markets	Reiterated Rating	Hold	$22.00	N/A	i
8/9/2016	UBS Group	Reiterated Rating	Buy	$30.00	N/A	i
8/5/2016	Morgan Stanley	Set Price Target	Hold	$15.00	N/A	i Rating by David Risinger at Morgan Stanley
7/26/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight	$40.00	N/A	i Rating by Chris Schott at JPMorgan Chase & Co.
7/8/2016	Piper Jaffray Companies	Reiterated Rating	Neutral	$25.00 ➝ $18.00	N/A	i Rating by David Amsellem at Piper Jaffray Companies
6/30/2016	Morgan Stanley	Reiterated Rating	Hold		N/A	i Rating by David Risinger at Morgan Stanley
6/29/2016	Oppenheimer	Reiterated Rating	Hold		N/A	i Rating by Rohit Vanjani at Oppenheimer Holdings Inc.
6/29/2016	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy	$30.00	N/A	i Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
6/29/2016	SVB Leerink	Reiterated Rating	Market Perform	$23.00	N/A	i Rating by Jason Gerberry at SVB Leerink LLC
6/29/2016	JMP Securities	Reiterated Rating	Buy		N/A	i Rating by Donald Ellis at JMP Securities
6/28/2016	BMO Capital Markets	Initiated Coverage	Market Perform	$21.00	N/A	i
6/25/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight		N/A	i Rating by Chris Schott at JPMorgan Chase & Co.
6/15/2016	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy	$31.00	N/A	i Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
6/13/2016	Mizuho	Upgrade	Underperform ➝ Neutral	$13.00 ➝ $16.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
6/6/2016	The Goldman Sachs Group	Initiated Coverage	Neutral	$20.00	N/A	i
5/18/2016	Royal Bank of Canada	Reiterated Rating	Sector Perform	$26.00	N/A	i Rating by Randall Stanicky at Royal Bank of Canada
5/18/2016	Stifel Nicolaus	Lower Price Target	Buy	$75.00 ➝ $25.00	N/A	i

(Data available from 5/16/2016 forward)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Today's Range

Now: $5.61

$5.48

$5.62

50 Day Range

MA: $6.29

$5.16

$7.90

52 Week Range

Now: $5.61

$2.71

$10.89

Volume

2,807,230 shs

Average Volume

3,819,250 shs

Market Capitalization

$1.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.41

Frequently Asked Questions

What sell-side analysts currently cover shares of Endo International?

The following Wall Street research analysts have issued reports on Endo International in the last twelve months: Barclays PLC, Citigroup Inc., Morgan Stanley, Piper Sandler, Royal Bank of Canada, SunTrust Banks, Inc., SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ENDP.

What is the current price target for Endo International?

6 Wall Street analysts have set twelve-month price targets for Endo International in the last year. Their average twelve-month price target is $7.67, suggesting a possible upside of 36.7%. Piper Sandler has the highest price target set, predicting ENDP will reach $12.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $3.00 for Endo International in the next year.
View the latest price targets for ENDP.

What is the current consensus analyst rating for Endo International?

Endo International currently has 2 sell ratings, 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ENDP, but not buy more shares or sell existing shares.
View the latest ratings for ENDP.

What other companies compete with Endo International?

Other companies that are similar to Endo International include Johnson & Johnson, Pfizer, AbbVie, Merck & Co., Inc., Eli Lilly and, Bristol-Myers Squibb, Zoetis, Royalty Pharma, Horizon Therapeutics Public, Jazz Pharmaceuticals, Perrigo, Nektar Therapeutics, Pacira BioSciences, Corcept Therapeutics and Supernus Pharmaceuticals.

How do I contact Endo International's investor relations team?

Endo International's physical mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company's listed phone number is 011-353-1268-2000 and its investor relations email address is [email protected] The official website for Endo International is www.endo.com.